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Abstract
Background: Retrospective studies indicate associations between TSER (thymidylate synthase enhancer region) genotypes
and clinical outcomes in patients receiving 5-FU based chemotherapy, but well-controlled prospective validation has been
lacking.
Methods: In this phase II study (NCT00515216 registered through ClinicalTrials.gov, http://clinicaltrials.gov/show/
NCT00515216), patients with ‘‘good risk’’ TSER genotypes (at least one TSER*2 allele) were treated with FOLFOX
chemotherapy to determine whether prospective patient selection can improve overall response rates (ORR) in patients
with gastric and gastroesophageal junction (GEJ) cancers, compared with historical outcomes in unselected patients
(estimated 43%).
Results: The ORR in genotype-selected patients was 39.1% (9 partial responses out of 23 evaluable patients, 95% CI, 22.2 to
59.2), not achieving the primary objective of improving ORR. An encouraging disease control rate (DCR, consisting of partial
responses and stable diseases) of 95.7% was noted and patients with homozygous TSER*2 genotype showed better tumor
response.
Conclusions: In this first prospective, multi-institutional study in patients with gastric or GEJ cancers, selecting patients with
at least one TSER*2 allele did not improve the ORR but led to an encouraging DCR. Further studies are needed to investigate
the utility of selecting patients homozygous for the TSER*2 allele and additional genomic markers in improving clinical
outcomes for patients with gastric and GEJ cancers.
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Introduction
Cancers of the gastric cardia, gastroesophageal junction (GEJ)
and distal esophagus have been rapidly increasing in incidence in
the past decades, especially in patients younger than 40 years of
age [1]. Unfortunately, 80–90% of newly diagnosed patients
present with regional or distant metastatic disease and even with
optimal therapy, the median survival in these patients is less than 1
year and survival at 5 years is essentially zero [2,3]. Recent
advances in our capacity to detect and target specific molecular
lesions in cancer cells and to obtain genetic information from
tumor tissues and patients allow for selection of optimal therapies,
improving the outcomes for these aggressive cancers. For example,
targeting HER-2 expressing gastroesophageal tumors with trastu-
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zumab led to an improvement in the survival of patients with
advanced disease [4]. However, for the majority of patients
selection of initial therapy remains largely empiric as most of the
regimens have similar response rates and median survival [3,5].
Thus, there is a clear need for approaches that can guide
treatment selection for the most effective regimens.
5-fluorouracil (5-FU) is one of the most commonly prescribed
chemotherapy agents. It has demonstrated preclinical synergy with
oxaliplatin in a variety of tumor types and this combination has
demonstrated clear efficacy in treating patients with gastric and
GEJ cancers [6–8]. Thymidylate synthase (TS, encoded by the
TYMS gene) is the critical enzyme in DNA synthesis and repair
and it is the primary target for 5-FU and other folate-based
antimetabolites [9]. Overexpression of TS has been linked to
clinical resistance to TS-targeted agents including 5-FU [10]. In
turn, genetic polymorphisms involving the promoter region of the
TYMS gene, specifically, the number of tandem repeat sequences
in the TS enhancer region (TSER - the 28-nucleotide G/C-rich
sequence in the 59-untranslated region) have been shown to be
important determinants of tumoral TS expression [11–15]. The
two most common TSER alleles are the two tandem repeats
(TSER*2, allelic frequency = 0.2,0.4) and the three tandem
repeats (TSER*3, allelic frequency = 0.6,0.8) [15].
Retrospective studies in colorectal cancer have demonstrated
that individuals with TSER*3/*3 genotype had a significantly
lower response rate and poorer outcomes to 5-FU compared with
those with at least one TSER*2 allele [11,16–18]. Additional
retrospective analyses of TS expression or TSER genotypes in
relation to clinical outcomes in patients with gastric cancers
replicated these findings [19,20]. More recently, findings from the
first prospective study evaluating the utility of TSER genotypes in
directing neoadjuvant chemoradiation for patients with rectal
carcinoma demonstrated that patients treated with 5-FU-based
chemoradiotherapy according to their TSER genotypes had
improved tumor downstaging [21]. Together, these studies
provide ample evidence that TS expression status and/or TSER
genotyping may be useful in selecting patients who are likely to
respond to treatment with 5-FU or its analogues.
This Phase II study was designed to prospectively select patients
with ‘‘good risk’’ TSER genotypes (i.e. TSER*2/*2 or *2/*3) and
treat them with a standard 5-FU-based regimen (FOLFOX; 5-FU,
leucovorin, oxaliplatin) in order to improve clinical outcomes in
patients with gastric and GEJ cancers. The primary end point of
this study was to determine whether TSER genotype-directed
chemotherapy would result in an improved overall response rate
(ORR, 60% or higher) compared to historical control response
rates in non-genotype selected patients (estimated 43%). The
secondary end points were to retrospectively assess whether other
genetic variations, in particular, additional polymorphic loci in the
TYMS gene and other genes involved in the disposition and
response to the FOLFOX regimen would influence the response in
the treated patients.
Materials and Methods
Ethics Statement
The trial was done in accordance with the Declaration of
Helsinki and ICH Good Clinical Practice. The study protocol was
approved by the Vanderbilt University and Washington Univer-
sity Institutional Review Boards and all participants provided their
written informed consent to participate in this study. The study
was registered through ClinicalTrials.gov (Identifier:
NCT00515216). The protocol for this trial and supporting
TREND checklist are available as supporting information; see
Checklist S1 and Protocol S1. The trial started (first patient
enrolled) in June 2008 and ended (last patient completed the
clinical study) in October 2010.
Eligibility
Adult ($18 years) patients who had histologically or cytolog-
ically confirmed adenocarcinoma of the stomach or GEJ and had
received no prior therapy for metastatic disease were eligible.
Subjects could have received prior neoadjuvant or adjuvant
therapy as long as the disease-free interval was longer than 6
months. Eligible patients had Eastern Cooperative Oncology
Group (ECOG) performance status #2, adequate organ and bone
marrow function, and an ability to understand and willingness to
sign written informed consent. Patients with known active brain
metastases, HIV on anti-retroviral therapy or other uncontrolled
intercurrent illnesses were excluded.
Study Design and Treatment
This was an open-label, non-randomized, investigator-initiated
multi-center study involving prospective genotyping (study flow
chart shown in Figure 1). Potentially eligible patients underwent a
blood draw for TSER genotyping. Patients with TSER*3/*3
genotype were not included in study treatment. Patients with
TSER*2/*2 or TSER*2/*3 genotypes received the modified
FOLFOX-6 treatment consisting of oxaliplatin 85 mg/m2 and
leucovorin 400 mg/m2 given over 2 hours along with 5-FU
400 mg/m2 given as an intravenous push over 5 minutes, followed
by 5-FU 2,400 mg/m2 given as an intravenous infusion of 46
hours. This treatment was repeated every 2 weeks in the absence
of unacceptable adverse events or disease progression.
Assessment of Efficacy and Toxicity
The patients were reevaluated for response every 8 weeks. In
addition to a baseline scan, confirmatory scans were performed
not less than 4 weeks following initial documentation of objective
response. Tumor response and progression were evaluated using
Response Evaluation Criteria in Solid Tumors (RECIST). Partial
Figure 1. A schematic diagram of the current phase II study
design.
doi:10.1371/journal.pone.0107424.g001
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response (PR) was defined as at least 30% decrease in the sum of
the longest diameter (LD) of target lesions, taking as reference the
baseline sum LD. Progressive disease (PD) was defined as at least a
20% increase in the sum of the LD of target lesions, taking as
reference the smallest sum LD recorded since the treatment
started or the appearance of one or more new lesions. Stable
disease (SD) was defined as neither sufficient shrinkage to qualify
for PR nor sufficient increase to qualify for PD. Toxicities were
graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE), version
3.0. Dose modifications were made depending on the type and
severity of toxicities observed.
Retrospective Genotyping Analyses
Retrospective genotyping analyses by restriction fragment
length polymorphism (RFLP) were performed for two additional
loci in the TYMS gene (G.C SNP within the second 28-bp
tandem repeat of the 3R allele, rs34743033; 1494delTTAAAG in
the 39-UTR, rs34489327) and five loci in additional genes
reported to be associated with response and toxicity to the
FOLFOX regimen (ERCC1, c.354C.T, rs11615; ERCC2,
c.2251A.C, rs13181; GSTP1, c.313A.G, rs1695; XRCC1,
c.1196G.A, rs25487; and MDR1, c.3435C.T, rs1045642).
Briefly, regions encompassing the respective polymorphisms were
PCR amplified (Platinum PCR Supermix, Invitrogen) and
subjected to restriction enzyme digest to yield the diagnostic
fragmentation patterns (detailed conditions provided in Table S1
in File S1) [13,22–30]. The digested and undigested products from
each patient sample were visualized on 3% agarose gel along with
positive controls whose genotypes were verified by direct
sequencing.
Statistical Analyses
The primary objective of this study was to test whether selection
of patients according to TSER genotypes would improve
treatment response rates compared to the response rates previously
reported in an unselected population. Sample size estimation was
based on the assumed response rate of 43% with this regimen in
an unselected population and improving the response rate to a
minimum of 60% based on the retrospective data [19,20]. An
Optimum MinMax two-stage accrual design was employed [31].
In the initial step, 45 eligible patients were to be entered into the
study, with a final accrual goal of 75 if $20 responses were
observed in the first group. This design provides 90% statistical
power to detect a difference of 17% with a two-sided significance
level of ,0.05. Unfortunately, the current study had to be
terminated earlier than the initial stopping point due to insufficient
funding. For 23 patients evaluable for tumor responses, univariate
associations between genotypes and tumor response (PR and SD)
were evaluated using Fisher’s exact test. Overall survival (OS) and
progression free survival (PFS) were analyzed using Kaplan-Meier
models and associations between genotypes and patient survival
were assessed using log-rank tests. No sub-analyses were
performed for potential associations between genotypes and
toxicities since they were not pre-specified in our analysis plans.
All statistical analyses were performed using R package (version
3.0.2).
Results
Patient characteristics
Patient baseline characteristics are listed in Table 1. Between
June 2008 and October 2010, 42 patients with gastric and GEJ
cancers were screened for their TSER genotypes; 26 patients
(63.4%) had good risk genotypes (TSER*2/*2 or *2/*3) and
enrolled onto the trial. One patient with a good risk genotype
withdrew consent and was not treated on study. The majority of
patients had gastric cancer (73%) and good performance status
(69% ECOG PS of 1 or better). The median age of the
participants was 56 years and a majority (62%) was male.
Treatment and toxicities
Twenty five patients received at least one dose of study
treatment with the modified FOLFOX-6 regimen. A total of
128 cycles were administered, with a median of 5.5 cycles per
patient (range, 0.5–15 cycles). The occurrence and the incidence
of the main toxicities are reported in Table 2. The toxicities
experienced by the study participants were within the expected
range for patients receiving treatment with FOLFOX. The most
common toxicities were hematologic with grade 3 and 4
neutropenia, leukopenia and anemia recorded in 8 out of 25
(32%), 4 out of 25 (16%), and one out of 25 (4%) patients,
respectively. Only two out of 25 patients experienced grade 3
gastrointestinal toxicity and no participants had grade 4 gastro-
intestinal toxicity. Neurotoxicity was common and was observed in
44% (grade 1 in 20%, grade 2 in 16% and grade 3 in 8%) of the
patients. Fatigue was also common and was observed in 52%
(grade 1 in 40%, grade 2 in 4% and grade 3 in 8%) of the patients.
No treatment-related deaths were reported.
Response to FOLFOX regimen, recurrence and survival
and TSER genotypes
Response to the modified FOLFOX-6 regimen in the 23
evaluable patients is shown in Table 3. Nine patients experienced
PR and no patient experienced complete response (CR), making
the overall response rate (CR+PR) to be 39.1% (95% confidence
interval (CI, Wilson), 22.2 to 59.2). When tumor responses are
compared between the two TSER genotype groups, patients with
the TSER*2/*2 genotype experienced a greater frequency of PR
and a less frequency of SD compared to those with the TSER*2/
*3 genotype (p = 0.02, Fisher’s exact test, Table 3). On the other
hand, only one out of 23 patients experienced PD, for an observed
disease control rate (CR+PR+SD) of 95.7% (95% CI, 79.0 to
99.2). OS and PFS plots for the enrolled patients are shown in
Figure 2. Median values for OS and PFS were 11.4 months (95%
CI, 6.3 to 16.3) and 6.2 months (95% CI, 5.2 to 8.6), respectively.
For both OS and PFS, patients with the TSER*2/*2 genotype had
a trend towards an improvement in median OS and PFS in
comparison to those patients with the TSER*2/*3 genotype
(Figure 3, OS, 20.9 vs 11.4 months; PFS, 10.2 vs 6.0 months).
Potential associations between tumor response and
retrospectively analyzed genetic variations
For 21 patients, the retrospective analyses for additional
genotypes reported to be associated with treatment responses
were completed (the genotypic and allelic frequencies of the
interrogated variations are summarized in Table S2 in File S1). Of
note, the frequency of TSER*2 allele is higher in our current study
than those reported in the literature since the patients with the
TSER*3/*3 genotype were excluded in this study. When the two
additional loci in the TYMS genes (rs34743033 and rs34489327)
were assessed for their potential association with tumor response
(PR vs SD), the results did not indicate any statistically significant
association (Table 4). Among the five additional genotypes
analyzed, two genetic variations in the XRCC1 (c.1196G.A,
rs25487) and MDR1 (c.3435C.T, rs1045642) genes displayed a
trend supportive of their potential association with tumor response
TYMS Genotype-Directed Chemotherapy
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(p = 0.050 and 0.056, respectively, Fisher’s exact test, Table 4).
However, no apparent association was observed when OS and
PFS times were compared among the groups with differing
genotypes at the five loci (Table S3 in File S1).
Discussion
This clinical study is unique in that we for the first time applied
the strategy of prospectively assessing TSER genotypes to improve
clinical outcomes in gastric and GEJ cancers. Our initial
hypothesis was that selection of patients with good risk TSER
genotypes would improve the response rate for FOLFOX to 60%,
a 17% increase over the historic control response rate of 43%
observed in non-genotype selected patients. The observed
response rate in this study was 39.1% (9 PR out of 23 patients
evaluable for tumor response, 95% CI 22.2 to 59.2), not achieving
the primary study endpoint. The median OS and PFS times of
11.3 and 6.2 months in patients with good risk TSER genotypes
were also comparable to those reported in non-genotype selected
populations (Figure 2). Although the observed response rate did
not support the utility of TSER genotyping as a treatment
selection guide, it should also be noted that the enrolled patients
experienced a very promising disease control rate of 95.7% (9 PR
and 13 SD out of 23 patients), higher than those reported in the
literature [32–36]. The high disease control rate in the current
study may provide the first prospectively obtained evidence for the
utility of TSER genotyping in improving clinical outcomes in
patients with gastric and GEJ cancers.
The apparent lack of treatment outcome improvement in
patients with good risk TSER genotypes may be related to the
small number of patients enrolled in the current study, therefore
necessitating further validation of this approach in a larger clinical
trial. It should be however noted that we observed a very
encouraging response rate of 83.3% in patients with the
homozygous TSER*2/*2 genotype (5 out of 6 patients experi-
enced PR). This observation was from a very small number of
patients, but it suggests that the improvement in clinical outcomes
in patients with gastric and GEJ cancers may require selection of
patients with two TSER*2 alleles. Alternatively, the current
findings may be related to the presence of multiple molecular/
genetic factors contributing to chemotherapy response. Strategies
involving more than one host and tumoral markers will likely be
more successful in guiding therapeutic decision making. Currently
we cannot rule out the possibility that TSER genotypes may have
prognostic value, independent of therapy, in patients with gastric
and GEJ cancers as previously reported in patients with colorectal
cancer [37,38]. Consideration of the above-mentioned aspects will
be important in the design of future clinical trials which can
evaluate multifactorial treatment selection approaches in a larger
number of patients.
The findings from another prospective study with selection of
patients on the basis of TSER genotypes have been recently
reported in rectal cancer patients receiving neoadjuvant chemor-
adiation (n = 135) [21]. In this particular study, patients with good
risk TSER genotypes (at least one TSER*2 allele) were treated
with standard 5-FU-based chemoradiation. Patients with good risk
genotypes had higher rates of downstaging and pathologic
complete response than reported in unselected populations.
Patients with poor risk TSER genotypes (harboring no TSER*2
allele) were treated with irinotecan in addition to 5-FU-based
Table 1. Baseline clinical and demographic characteristics of enrolled patients (n = 26).
Characteristic Patients (n = 26)
No %
TSER genotypes
TSER*2/*2 5 19
TSER*2/*3 21 81
Gender
Male 16 62
Female 10 38
Age (years)
median 56
range 26–81
Ethnicity
Caucasians 23 88
African Americans 2 8
Not reported 1 4
ECOG performance status
0 5 19
1 13 50
2 8 31
Primary tumor type
Gastric 19 73
Gastroesophageal junction (GEJ) 7 27
Prior neoadjuvant or adjuvant therapy (.6 months) 2 8
doi:10.1371/journal.pone.0107424.t001
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chemoradiation. Patients in the poor risk groups receiving
additional therapies also showed higher rates of downstaging
and pathologic complete response than those for unselected
population. This study [21] however did not address whether
patients in the poor risk group would have had poorer clinical
outcomes if they had not received additional irinotecan therapy.
Nevertheless, these findings certainly support the utility of this
single genotype-based strategy in improving the clinical outcomes
of rectal cancer patients.
Table 3. Tumor responses to the FOLFOX regimen in patients of differing TSER genotypes.
Tumor response TSER genotypes P-valuea
TSER*2/*2 TSER*2/*3
(n = 6) (n = 17)
No % No %
PD (n = 1) 0 0 1 5.9 0.02
PR (n = 9) 5 83.3 4 23.5
SD (n = 13) 1 16.7 12 70.6
PD, progressive disease; PR, partial response; SD, stable disease.
aCalculated using Fisher’s exact test for the association between response (PR and SD) and TSER genotype.
doi:10.1371/journal.pone.0107424.t003
Figure 2. Kaplan-Meier curves showing overall survival (A) and
progression free survival (B) with 95% confidence intervals (CI)
in the patients enrolled.
doi:10.1371/journal.pone.0107424.g002
Figure 3. Kaplan-Meier curves showing overall survival (A) and
progression free survival (B) according to TSER genotypes.
doi:10.1371/journal.pone.0107424.g003
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No improvement in the overall response rate from this study
echo the inconsistent results observed in previous studies utilizing
TSER genotyping in treating patients with gastric and esophageal
cancers [6,39–41]. Less than expected response rates in our
current study as well as other previously reported retrospective
studies may be explained by the potential effect of oxaliplatin on
tumoral TS expression. The clinical synergy of combining 5-FU
with oxaliplatin is well documented and is key to the success and
frequent use of this combination regimen [42–44]. One proposed
explanation for this synergy is oxaliplatin-induced TS downreg-
ulation by as yet unexplained mechanisms [45,46]. If oxaliplatin
were to cause tumoral TS downregulation or any potential
molecular changes influencing tumor response, any benefits from
pretreatment TSER genotyping may have been obscured in our
current study. Interestingly, some in vitro studies also indicate that
irinotecan may also decrease TS activities and protein levels where
irinotecan could overcome 5-FU resistance in tumors [47,48].
These observations could help to explain the favorable response
results in the ‘‘poor risk’’ patients who received irinotecan in the
Tan et al. study [21]. However, our current study design of a single
arm (patients with the favorable TSER genotypes only) does not
allow us to gather treatment outcome for patients with the
unfavorable TSER genotypes. Our initial study design was indeed
two-armed (favorable vs. unfavorable TSER genotypes). But, the
reviewers in the NIH study section recommended that we revise
our study to be single armed for patients with favorable TSER
genotypes given the patient numbers and other resources
available. In future clinical trials, it would be certainly interesting
to prospectively compare treatment outcomes of patients with
favorable and unfavorable TSER genotypes.
Retrospective analyses for two additional TYMS genotypes
showed no significant association with tumor response (Table 4).
For additional non-TYMS genes analyzed, XRCC1 (c.1196G.A,
rs25487) and MDR1 (c.3435C.T, rs1045642) showed a potential
association to tumor response (Table 4). We performed these
analyses based on the previous findings on the potential association
between these genotypes and clinical outcomes in colorectal
cancer patients treated with FOLFOX [24,29,40]. However, we
did not observe any strong association between the tested
genotypes and tumor response, except a trend reflective of
Table 4. Univariate association between additional retrospectively analyzed genotypes and tumor response (PR: partial response
and SD: stable disease).
Gene Genotype Tumor response P-valuea
PR (N = 9) SD (N = 11)
No. % No. %
TYMS 59-UTR TSER + G.C (rs34743033)
TSER*2/*2 5 56 1 9
TSER*2/*3(G) 2 22 4 36
TSER*2/*3(C) 2 22 6 55 0.137
TYMS 39-UTR 1494delTTAAAG(6 bp) (rs34489327)
+6 bp/+6 bp 5 56 6 55
+6 bp/26 bp 4 44 5 45 1
ERCC1 c.354C.T (rs11615)
C/C 2 22 1 9
C/T 4 45 8 73
T/T 3 33 2 18 0.552
ERCC2 c.2251A.C (rs13181)
A/A 5 56 3 27
A/C 3 33 6 55
C/C 1 11 2 18 0.485
GSTP1 c.313A.G (rs1695)
A/A 4 45 8 73
A/G 3 33 2 18
G/G 2 22 1 9 0.552
XRCC1 c.1196G.A (rs25487)
A/A 1 11 6 55
G/A 6 67 5 45
G/G 2 22 0 - 0.050
MDR1 c.3435C.T (rs1045642)
C/C 0 - 1 9
C/T 9 100 6 55
T/T 0 - 4 36 0.056
aCalculated using Fisher’s exact test.
doi:10.1371/journal.pone.0107424.t004
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potential associations for XRCC1 and MDR1. Similar negative
results have been reported from retrospective analyses of TYMS
and non-TYMS genotypes in relation to the histopathological
tumor responses in patients with gastric and esophageal cancers
[39,41,49]. Interestingly, the polymorphisms in XRCC1 and
MDR1 have been associated with clinical outcomes in gastric
and colorectal cancer [24,50]. Further investigation in larger
clinical trials is warranted to determine whether our current
findings are indicative of varying impact of the tested genotypes in
different tumor types.
In summary, our strategy to improve response rates in patients
with gastric and GEJ cancers by pretreatment TSER genotyping
was unsuccessful, but even in the setting of some limitations of our
current study the high disease control rate was encouraging. The
future applicability of a single polymorphism strategy to guide
therapy selection, while feasible and attractive, does not appear to
yield results of sufficient impact to be generally applicable. Our
approach may aid in selecting patients who require chemotherapy
intensification to achieve favorable results by adding oxaliplatin or
irinotecan and avoid chemotherapy toxicities in those who may
have a favorable outcome with 5-FU alone. The contemporary
confluence of our capacity to molecularly target cancers and the
advancement of our ability to characterize patients and their
cancers using molecular genetics will allow for multiple variables
to be considered and applied towards improvements in cancer
care. TYMS polymorphism status does not appear to be a
singularly important treatment selection factor, but it may be a key
contributor to favorable outcomes in a multivariable genomically
based therapeutic approach.
Supporting Information
File S1 Supporting Tables.
(DOCX)
Checklist S1 TREND Checklist.
(PDF)
Protocol S1 Trial Protocol.
(PDF)
Acknowledgments
The Vanderbilt University CHGR/CRC DNA Resources Core provided
technical assistance for this work.
Author Contributions
Conceived and designed the experiments: ACL WL HLM. Performed the
experiments: LWG BRT ACL EC DBC JDB JP AWG NT BZ WL CF.
Analyzed the data: LD WL LWG ACL. Contributed reagents/materials/
analysis tools: LD. Contributed to the writing of the manuscript: LWG NT
EC BRT DBC HLM JDB BZ AWG WL ACL.
References
1. Brown LM, Devesa SS (2002) Epidemiologic trends in esophageal and gastric
cancer in the United States. Surg Oncol Clin N Am 11: 235–256.
2. Polednak AP (2003) Trends in survival for both histologic types of esophageal
cancer in US surveillance, epidemiology and end results areas. Int J Cancer 105:
98–100.
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, et al. (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
N Engl J Med 358: 36–46.
4. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for
treatment of HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:
687–697.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, et al.
(2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with
cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a
report of the V325 Study Group. J Clin Oncol 24: 4991–4997.
6. Keam B, Im SA, Han SW, Ham HS, Kim MA, et al. (2008) Modified
FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study
and comprehensive analysis of polymorphisms as a predictive and prognostic
marker. BMC Cancer 8: 148.
7. Oh SY, Kwon HC, Seo BG, Kim SH, Kim JS, et al. (2007) A phase II study of
oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-
fluorouracil (modified FOLFOX-4) as first line therapy for patients with
advanced gastric cancer. Acta Oncol 46: 336–341.
8. De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, et al. (2005) A
phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic
acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
Br J Cancer 92: 1644–1649.
9. Chu E, Moto AC, Fogarasi MC (2001) Cancer: Principles & Practice of
Oncology; De Vita JVT, Hellman S, Rosenberg SA, editors. Philadelphia:
Lippincott Williams & Wilkins. 388–415 p.
10. Marsh S, McLeod HL (2001) Thymidylate synthase pharmacogenetics in
colorectal cancer. [see comment]. Clin Colorectal Cancer 1: 175–178; discussion
179–181.
11. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K (1995) Functional analysis and
DNA polymorphism of the tandemly repeated sequences in the 59-terminal
regulatory region of the human gene for thymidylate synthase. Cell Struct Funct
20: 191–197.
12. Kawakami K, Omura K, Kanehira E, Watanabe Y (1999) Polymorphic tandem
repeats in the thymidylate synthase gene is associated with its protein expression
in human gastrointestinal cancers. Anticancer Res 19: 3249–3252.
13. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, et al. (2000) Searching
expressed sequence tag databases: discovery and confirmation of a common
polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers
Prev 9: 1381–1385.
14. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, et al. (2001)
Different lengths of a polymorphic repeat sequence in the thymidylate synthase
gene affect translational efficiency but not its gene expression. Clin Cancer Res
7: 4096–4101.
15. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL (1999) Ethnic variation in
the thymidylate synthase enhancer region polymorphism among Caucasian and
Asian populations. Genomics 58: 310–312.
16. Iacopetta B, Grieu F, Joseph D, Elsaleh H (2001) A polymorphism in the
enhancer region of the thymidylate synthase promoter influences the survival of
colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85: 827–830.
17. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, et al. (2001)
Thymidylate synthase gene polymorphism determines response and toxicity of 5-
FU chemotherapy. Pharmacogenomics J 1: 65–70.
18. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, et
al. (2001) Polymorphisms of the repeated sequences in the enhancer region of
the thymidylate synthase gene promoter may predict downstaging after
preoperative chemoradiation in rectal cancer. J Clin Oncol 19: 1779–1786.
19. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, et al.
(1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in
predicting response and survival for gastric cancer patients receiving combina-
tion cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309–316.
20. Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, et al. (1998) High expression of
thymidylate synthase is associated with the drug resistance of gastric carcinoma
to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82: 1626–
1631.
21. Tan BR, Thomas F, Myerson RJ, Zehnbauer B, Trinkaus K, et al. (2011)
Thymidylate synthase genotype-directed neoadjuvant chemoradiation for
patients with rectal adenocarcinoma. J Clin Oncol 29: 875–883.
22. Henriquez-Hernandez LA, Murias-Rosales A, Hernandez Gonzalez A, Cabrera
De Leon A, Diaz-Chico BN, et al. (2009) Gene polymorphisms in TYMS,
MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study.
Oncol Rep 22: 1425–1433.
23. Lincz LF, Scorgie FE, Garg MB, Ackland SP (2007) Identification of a novel
single nucleotide polymorphism in the first tandem repeat sequence of the
thymidylate synthase 2R allele. Int J Cancer 120: 1930–1934.
24. Huang MY, Huang ML, Chen MJ, Lu CY, Chen CF, et al. (2011) Multiple
genetic polymorphisms in the prediction of clinical outcome of metastatic
colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
Pharmacogenet Genomics 21: 18–25.
25. Huang MY, Fang WY, Lee SC, Cheng TL, Wang JY, et al. (2008) ERCC2
2251A.C genetic polymorphism was highly correlated with early relapse in
high-risk stage II and stage III colorectal cancer patients: a preliminary study.
BMC Cancer 8: 50.
26. Zhang XH, Zhang X, Zhang L, Chen Q, Yang Z, et al. (2012) XRCC1
Arg399Gln was associated with repair capacity for DNA damage induced by
occupational chromium exposure. BMC Res Notes 5: 263.
TYMS Genotype-Directed Chemotherapy
PLOS ONE | www.plosone.org 8 September 2014 | Volume 9 | Issue 9 | e107424
27. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA (1999) XRCC1
polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant
frequency. Cancer Res 59: 2557–2561.
28. Zhang Z, Wan J, Jin X, Jin T, Shen H, et al. (2005) Genetic polymorphisms in
XRCC1, APE1, ADPRT, XRCC2, and XRCC3 and risk of chronic benzene
poisoning in a Chinese occupational population. Cancer Epidemiol Biomarkers
Prev 14: 2614–2619.
29. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, et al.
(2003) A novel single nucleotide polymorphism within the 59 tandem repeat
polymorphism of the thymidylate synthase gene abolishes USF-1 binding and
alters transcriptional activity. Cancer Res 63: 2898–2904.
30. Kawakami K, Watanabe G (2003) Identification and functional analysis of single
nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase
gene. Cancer Res 63: 6004–6007.
31. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control
Clin Trials 10: 1–10.
32. Ocvirk J, Rebersek M, Skof E, Hlebanja Z, Boc M (2012) Randomized
prospective phase II study to compare the combination chemotherapy regimen
epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capeci-
tabine in patients with advanced or metastatic gastric cancer. Am J Clin Oncol
35: 237–241.
33. Moon YW, Rha SY, Jeung HC, Kim C, Hong MH, et al. (2010) Outcomes of
multiple salvage chemotherapy for advanced gastric cancer: implications for
clinical practice and trial design. Cancer Chemother Pharmacol 66: 797–805.
34. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, et al. (2011)
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment
in advanced gastroesophageal cancer: a prospective multi-center biomarker-
oriented phase II study. Ann Oncol 22: 1358–1366.
35. Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, et al. (2010) Phase II
study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer
(G-SOX study). Ann Oncol 21: 1001–1005.
36. Amarantidis K, Xenidis N, Chelis L, Chamalidou E, Dimopoulos P, et al. (2011)
Docetaxel plus oxaliplatin in combination with capecitabine as first-line
treatment for advanced gastric cancer. Oncology 80: 359–365.
37. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, et al. (2000)
Thymidylate synthase expression: an independent prognostic factor for local
recurrence, distant metastasis, disease-free and overall survival in rectal cancer.
Clin Cancer Res 6: 1378–1384.
38. Popat S, Matakidou A, Houlston RS (2004) Thymidylate synthase expression
and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin
Oncol 22: 529–536.
39. Ott K, Vogelsang H, Marton N, Becker K, Lordick F, et al. (2006) The
thymidylate synthase tandem repeat promoter polymorphism: A predictor for
tumor-related survival in neoadjuvant treated locally advanced gastric cancer.
Int J Cancer 119: 2885–2894.
40. Kawakami K, Graziano F, Watanabe G, Ruzzo A, Santini D, et al. (2005)
Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients
treated with surgery and adjuvant chemotherapy. Clin Cancer Res 11: 3778–
3783.
41. Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, et al. (2007)
Favorable genetic polymorphisms predictive of clinical outcome of chemor-
adiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.
Am J Clin Oncol 30: 252–257.
42. Lordick F, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, et al. (2005)
Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid
(FUFOX regimen) as first-line treatment in metastatic gastric cancer.
Br J Cancer 93: 190–194.
43. Chao Y, Yeh KH, Chang CJ, Chen LT, Chao TY, et al. (2004) Phase II study of
weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid
in the treatment of advanced gastric cancer. Br J Cancer 91: 453–458.
44. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, et al. (2003)
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either
therapy alone in patients with progressive colorectal cancer after irinotecan and
fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:
2059–2069.
45. Yeh KH, Cheng AL, Wan JP, Lin CS, Liu CC (2004) Down-regulation of
thymidylate synthase expression and its steady-state mRNA by oxaliplatin in
colon cancer cells. Anticancer Drugs 15: 371–376.
46. Chen CC, Chen LT, Tsou TC, Pan WY, Kuo CC, et al. (2007) Combined
modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line
with enhanced sensitivity to 5-fluorouracil. Br J Cancer 97: 334–344.
47. Fukushima M, Sakamoto K, Ohshimo H, Nakagawa F, Taguchi T (2010)
Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer
xenografts by down-regulation of intratumoral thymidylate synthase. Oncol Rep
24: 835–842.
48. Torigoe S, Ogata Y, Matono K, Shirouzu K (2009) Molecular mechanisms of
sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination
therapy against colon cancer cells. Anticancer Res 29: 2083–2089.
49. Toriumi F, Kubota T, Saikawa Y, Yoshida M, Otani Y, et al. (2004)
Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydroge-
nase mRNA level as an indicator in determining chemosensitivity to 5-
fluorouracil in advanced gastric carcinoma. Anticancer Res 24: 2455–2463.
50. Li Y, Yan PW, Huang XE, Li CG (2011) MDR1 gene C3435 T polymorphism
is associated with clinical outcomes in gastric cancer patients treated with
postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev 12: 2405–2409.
TYMS Genotype-Directed Chemotherapy
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e107424
